66 related articles for article (PubMed ID: 19422402)
1. Successful switch from insulin therapy to treatment with pioglitazone in type 2 diabetes patients with residual beta-cell function: results from the PioSwitch study.
Hohberg C; Pfützner A; Forst T; Lübben G; Karagiannis E; Borchert M; Schöndorf T
Diabetes Obes Metab; 2009 May; 11(5):464-71. PubMed ID: 19422402
[TBL] [Abstract][Full Text] [Related]
2. Limitations of the HOMA-B score for assessment of beta-cell functionality in interventional trials-results from the PIOglim study.
Pfützner A; Derwahl M; Jacob S; Hohberg C; Blümner E; Lehmann U; Fuchs W; Forst T
Diabetes Technol Ther; 2010 Aug; 12(8):599-604. PubMed ID: 20615100
[TBL] [Abstract][Full Text] [Related]
3. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
Miyazaki Y; DeFronzo RA
Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
[TBL] [Abstract][Full Text] [Related]
4. Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes.
Tan MH; Johns D; Strand J; Halse J; Madsbad S; Eriksson JW; Clausen J; Konkoy CS; Herz M;
Diabet Med; 2004 Aug; 21(8):859-66. PubMed ID: 15270789
[TBL] [Abstract][Full Text] [Related]
5. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
Derosa G; Maffioli P; Ferrari I; Mereu R; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Salvadeo SA
Horm Metab Res; 2010 Aug; 42(9):663-9. PubMed ID: 20560108
[TBL] [Abstract][Full Text] [Related]
6. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
Umpierrez G; Issa M; Vlajnic A
Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
[TBL] [Abstract][Full Text] [Related]
7. Combined metformin and insulin therapy for patients with type 2 diabetes mellitus.
Ponssen HH; Elte JW; Lehert P; Schouten JP; Bets D
Clin Ther; 2000 Jun; 22(6):709-18. PubMed ID: 10929918
[TBL] [Abstract][Full Text] [Related]
8. An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study.
Wallace TM; Levy JC; Matthews DR
Diabet Med; 2004 Jun; 21(6):568-76. PubMed ID: 15154941
[TBL] [Abstract][Full Text] [Related]
9. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
[TBL] [Abstract][Full Text] [Related]
10. Inhaled insulin as adjunctive therapy in subjects with type 2 diabetes failing oral agents: a controlled proof-of-concept study.
Hausmann M; Dellweg S; Osborn C; Heinemann L; Buchwald A; Rosskamp R; Genova P; Heise T
Diabetes Obes Metab; 2006 Sep; 8(5):574-80. PubMed ID: 16918593
[TBL] [Abstract][Full Text] [Related]
11. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus.
Sharma PK; Bhansali A; Sialy R; Malhotra S; Pandhi P
Clin Endocrinol (Oxf); 2006 Dec; 65(6):722-8. PubMed ID: 17121522
[TBL] [Abstract][Full Text] [Related]
12. Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study.
Davidson JA; Perez A; Zhang J;
Diabetes Obes Metab; 2006 Mar; 8(2):164-74. PubMed ID: 16448520
[TBL] [Abstract][Full Text] [Related]
13. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial.
Charbonnel BH; Matthews DR; Schernthaner G; Hanefeld M; Brunetti P;
Diabet Med; 2005 Apr; 22(4):399-405. PubMed ID: 15787663
[TBL] [Abstract][Full Text] [Related]
14. Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus type 2.
Forst T; Lübben G; Hohberg C; Kann P; Sachara C; Gottschall V; Friedrich C; Rosskopf R; Pfützner A
Microcirculation; 2005; 12(7):543-50. PubMed ID: 16207627
[TBL] [Abstract][Full Text] [Related]
15. Pioneer study: PPARgamma activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose control.
Pfützner A; Hohberg C; Lübben G; Pahler S; Pfützner AH; Kann P; Forst T
Horm Metab Res; 2005 Aug; 37(8):510-5. PubMed ID: 16138265
[TBL] [Abstract][Full Text] [Related]
16. Combination-therapy with bedtime nph insulin and sulphonylureas gives similar glycaemic control but lower weight gain than insulin twice daily in patients with type 2 diabetes.
Olsson PO; Lindström T
Diabetes Metab; 2002 Sep; 28(4 Pt 1):272-7. PubMed ID: 12442064
[TBL] [Abstract][Full Text] [Related]
17. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Gravina A; Fogari E; Maffioli P; Cicero AF
Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
[TBL] [Abstract][Full Text] [Related]
19. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.
van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ
Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of pioglitazone in type 2 diabetes mellitus: a postmarketing observational study.
Nafrialdi
Acta Med Indones; 2012 Jan; 44(1):28-34. PubMed ID: 22451182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]